AMH and breast cancer: From an oncological perspective, as BRCA1/2 protein defects sensitize breast tumor cells to various chemotherapeutic agents that induce DNA lesions [17, 24, 25], we investigated whether there was an association between tumor response to NAC and changes in AMH concentrations during NAC in breast cancer patients.